1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) Hypoxanthine guanine phosphoribosyltransferase (HPRT)-1 deficiency HPRT1 deficiency HPRT deficiency HPRT deficiency, complete HPRT deficiency, grade IV 1.2 OMIM# of the disease 300322.
1.3 Name of the analyzed genes or DNA/chromosome segments HPRT1.
OMIM# of the gene(s)
308000.
Mutational spectrum
Human HPRT is encoded by a single structural gene spanning approximately 45 kb on the long arm of the X chromosome at Xq26, and consists of nine exons with a coding sequence of 654 bp. Documented mutations in HPRT deficiency show a high degree of heterogeneity in type and location within the HPRT1 gene: deletions, insertions, duplications, and point mutations have been described as the cause of HPRT deficiency. To date, more than 300 diseaseassociated mutations have been found. [1] [2] [3] [4] 1.6 Analytical methods HPRT1 gene is a housekeeping gene and it is expressed in peripheral blood. Most HPRT-deficient patients, biochemically diagnosed by a null HPRT activity in erythrocytes, present HPRT mRNA expression, and molecular diagnosis can be accomplished by RNA extraction, reverse transcription-PCR, and HPRT complementary DNA (including 3¢ and 5¢ regions) sequencing. In other cases, genomic DNA sequencing of the nine HPRT1 exons, with its intronic flanquing sequences, may be necessary. In some cases, the HPRT coding region is normal and the patients present a decrease HPRT mRNA expression of unknown origin. In these patients quantification of HPRT mRNA by real-time PCR may be used for molecular diagnosis. [5] [6] [7] [8] [9] Inheritance of HPRT deficiency is X-linked recessive. Thus, males are generally affected and heterozygous females are carriers.
However, at least five females with Lesch-Nyhan syndrome have been described, with different molecular alterations accounting for their HPRT deficiency. [10] [11] [12] [13] [14] [15] [16] Carrier diagnosis is an important issue for most HPRT-deficient families. Female carriers cannot be detected without the help of a laboratory, as they are usually asymptomatic. Carrier status cannot be accurately assessed by biochemical and enzymatic methods. HPRT activity is most often normal in hemolysate of the peripheral blood of female carriers due to selection against HPRT-deficient erythrocyte precursors. Enzymatic diagnosis of the carrier state can be performed by the identification of HPRT-deficient hair follicles or cultured fibroblasts because of their mosaicism in terms of HPRT activity, although such diagnosis is not infallible. HPRT-deficient cells from carrier females can be selected based on their 6-thioguanine resistances. Proliferation assay of peripheral blood T lymphocytes in the presence of 6-thioguanine is diagnostic in most cases. However, faster and more accurate carrier diagnosis can be performed by molecular methods. Carrier diagnosis can be accomplished by genomic DNA sequencing of the HPRT1 gene fragment where the mutation was found in the family propositus. When propositus mutation is not available, amplification of the nine HPRT1 exons, with its intronic flanquing sequences, may be necessary. If a deletion has been found in the propositus, gene dosage may be accomplished by quantitative PCR or multiplex ligation-dependent probe amplification. [17] [18] Prenatal diagnosis for Lesch-Nyhan syndrome can be performed with amniotic cells obtained by amniocentesis at about 15-18 week's gestation, or chorionic villus cells obtained at about 10-12 week's gestation. Both HPRT enzymatic assay and molecular analysis for the known disease-causing mutation can be performed.
Analytical validation
Mutation found in HPRT complementary DNA must be confirmed at genomic level.
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence):
The prevalence of the disease is estimated to be 1/380 000 live births in Canada, and 1/235 000 live births in Spain. 19 1.9 If applicable, prevalence in the ethnic group of investigated person There is no difference in prevalence for a specific ethnic group.
Diagnostic setting
Comment: When enzymatic diagnosis is not available clinical and molecular diagnosis must be performed.
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
About 95% (In a 5% of patients the molecular defect causing HPRT deficiency is not found. These patients present decreased HPRT1 expression of unknown cause.) 2.2 Analytical specificity (proportion of negative tests if the genotype is not present) 100%.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be performed case by case.
About 95% (In a 5% of patients the molecular defect causing HPRT deficiency is not found. These patients present decreased HPRT1 expression of unknown cause.)
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be performed case by case. 100%.
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
100%.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: 100%. Index case in that family had not been tested:
In some rare cases (5%) standard genetic tests are not informative for diagnosis in spite of the HPRT enzymatic activity is null or decreased. In these cases diagnosis has to be made by enzymatic methods. (To be answered, if in 1.10 'A' was marked) 3.1.1 Can a diagnosis be performed other than through a genetic test? 3.1.2 Describe the burden of alternative diagnostic methods to the patient Enzymatic test for HPRT activity in hemolysate or intact cells are of diagnostic and pronostic value.
CLINICAL UTILITY
(Differential) diagnosis: the tested person is clinically affected
How is the cost-effectiveness of alternative diagnostic methods to be judged?
Enzymatic test are laborious and they are not available in many laboratories (see http://www.lesch-nyhan.org and http://www.orpha.net for the list).
Will disease management be influenced by the result of a genetic test?
3.2 Predictive setting: the tested person is clinically unaffected but carries an increased risk based on family history (To be answered, if in 1.10 'B' was marked) 
Prenatal diagnosis
(To be answered, if in 1.10 'D' was marked) Prenatal diagnosis possible when the causal mutation identified in the index case and diagnosis of the carrier performed.
3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnostic? Yes.
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe).
Molecular diagnosis in the proband allows a more accurate and faster carrier and prenatal diagnosis in relatives.
